A high-throughput screen for candidate agents that may reverse gamma-globin silen
A high-throughput screen for candidate agents that may reverse gamma-globin silen
批准号:
7532720
负责人:
David Ian Kingston Martin
金额:
$24.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2011-06-30
关键词:
Acute Erythroblastic LeukemiaAdultAffectAliquotBiological AssayBiological ModelsCaringCell Culture TechniquesCell LineCellsCessation of lifeChemicalsChildhoodChromatinClone CellsCountryCulture MediaDeveloped CountriesDeveloping CountriesDiseaseEpigenetic ProcessErythrocytesErythroid CellsEukaryotaFailureFluorescence-Activated Cell SortingGenesGenomeGenomicsGlobinGoalsHealthcare SystemsHemoglobinopathiesHereditary DiseaseHistone Deacetylase InhibitorIndividualLeadLifeMammalian CellMedicalMethodologyMethodsMolecularMorbidity - disease rateMusNaturePharmaceutical PreparationsPilot ProjectsProceduresProductionPublic HealthPublishingReporterReporter GenesSafetyScreening procedureSickle Cell AnemiaSiteSolutionsSorting - Cell MovementStagingSystemTestingThalassemiaTherapeutic AgentsTransgenesbasecell typeearly childhoodeffective therapyerythroid differentiationexperiencefetal globingamma Globinhigh throughput screeningmortalitynovelpreventpublic health relevanceresponsescale upsmall molecule librariestooltransgene expression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ?-hemoglobinopathies sickle cell disease and ?-thalassemia are among the most common, and most devastating, genetic diseases worldwide. In countries with developed health care systems, care for affected individuals is extremely expensive; in developing countries most affected individuals receive substandard or no care, and death in childhood is common. It has long been known that enhanced production of (fetal) ?-globin expression can ameliorate or prevent both diseases, as ?-globin substitutes for the defective ?-globin. A safe and effective drug that will accomplish this has long been sought, but it has been difficult to devise effective high-throughput assays. Here we propose to develop an assay that may produce candidate compounds that have activity in reversing ?-globin silencing in adult-stage red blood cells. This is a cell-based assay that relies on a new application of tried methodology developed by the PI; it is capable of screening many thousands of compounds. These compounds may serve as leads to new classes of active molecules, and can be tested for specific activity in experimental systems that reproduce globin switching. This is a pilot study intended to develop and explore the assay, but the initial testing has revealed that it is capable of identifying compounds with previously undescribed epigenetic activity. This study could thus open a new avenue of approach to a stubborn problem, the solution to which could affect millions of lives worldwide. PUBLIC HEALTH RELEVANCE: Sickle cell disease and _-thalassemia are devastating genetic diseases that are extremely common worldwide and increasingly common in the USA; current medical treatment for them is inadequate and expensive. A cheap and effective drug that could reactivate fetal globin expression would have a major impact on worldwide morbidity and mortality from these diseases, and ease a considerable burden on the health care systems of many developing countries. This proposal presents a new method of searching for chemical compounds that might provide such a cheap and effective treatment; thus it has a potential for a broad impact on public health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A high-throughput screen for candidate agents that may reverse gamma-globin silen
-
批准号:7851313
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2009
-
负责人:David Ian Kingston Martin
-
依托单位:
An Assay to Identify and Classify Epimutagens
-
批准号:7655389
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2008
-
负责人:David Ian Kingston Martin
-
依托单位:
An Assay to Identify and Classify Epimutagens
-
批准号:7441234
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2008
-
负责人:David Ian Kingston Martin
-
依托单位:
Diet, Epigenetic Events, And Cancer Prevention
-
批准号:6958770
-
项目类别:
-
资助金额:$31.62万
-
财政年份:2005
-
负责人:David Ian Kingston Martin
-
依托单位:
Diet, Epigenetic Events, And Cancer Prevention
-
批准号:7426862
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2005
-
负责人:David Ian Kingston Martin
-
依托单位:
Diet, Epigenetic Events, And Cancer Prevention
-
批准号:7628081
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2005
-
负责人:David Ian Kingston Martin
-
依托单位:
Epigenetic Suppression of the Obese Yellow Phenotype
-
批准号:7102832
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2005
-
负责人:David Ian Kingston Martin
-
依托单位:
Germline epimutation of hMLH1 as a factor in HNPCC
-
批准号:7076832
-
项目类别:
-
资助金额:$13.45万
-
财政年份:2005
-
负责人:David Ian Kingston Martin
-
依托单位:
Germline epimutation of hMLH1 as a factor in HNPCC
-
批准号:6856870
-
项目类别:
-
资助金额:$13.77万
-
财政年份:2005
-
负责人:David Ian Kingston Martin
-
依托单位:
Diet, Epigenetic Events, And Cancer Prevention
-
批准号:7238704
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2005
-
负责人:David Ian Kingston Martin
-
依托单位:
DONOR CD8 EFFECTOR FUNCTION IN MARROW TRANSPLANTATION
-
批准号:2655283
-
项目类别:
-
资助金额:$22.44万
-
财政年份:1996
-
负责人:David Ian Kingston Martin
-
依托单位:
GLOBIN GENE REGULATION BY RC TRANSCRIPTION FACTOR GATA-1
-
批准号:3367944
-
项目类别:
-
资助金额:$18.1万
-
财政年份:1992
-
负责人:David Ian Kingston Martin
-
依托单位:
GLOBIN GENE REGULATION BY RC TRANSCRIPTION FACTOR GATA-1
-
批准号:3367943
-
项目类别:
-
资助金额:$18.12万
-
财政年份:1992
-
负责人:David Ian Kingston Martin
-
依托单位:
PLACEBO CONTROLLED STUDY OF LAMIVUDINE AND INTRON A IN CHRONIC HEPATITIS B
-
批准号:6118403
-
项目类别:
-
资助金额:$2.51万
-
财政年份:--
-
负责人:David Ian Kingston Martin
-
依托单位:
海外基金